Boehringer Ingelheim and Palatin Technologies announce a global research collaboration to develop an innovative therapy for retinal diseases, focusing on diabetic retinopathy.
Diabetic retinopathy affects one in three people with diabetes, leading to vision loss and increased healthcare costs.
The collaboration aims to address the unmet need for new approaches in treating retinal diseases, such as diabetic macular edema.
Collaboration Strengthens Pipeline
Boehringer's pipeline in Eye Health receives a boost with the collaboration, enhancing its commitment to vision preservation.
Targeting Key Drivers of Retinal Diseases
Melanocortin receptor agonists offer a differentiated mechanism to target inflammation, vascular dysfunction, and neurodegeneration in retinal diseases.
Market Impact
Palatin to receive milestone payments up to €280 million, along with royalties on net sales, under the agreement with Boehringer.
- The collaboration addresses the high treatment burden associated with diabetic retinopathy, offering hope for patients facing vision loss and long-term care.
- Boehringer's expertise combined with Palatin's portfolio of melanocortin agonists indicates promising clinical and commercial potential in retinal health.
The collaboration between Boehringer Ingelheim and Palatin Technologies signifies a milestone in advancing treatments for retinal diseases, particularly diabetic retinopathy. The innovative approach holds promise for improving patient outcomes and addressing critical unmet needs in retinal health.